North American AIDS Cohorts on Collaboration and Design (NAACCORD)

北美艾滋病队列研究与设计合作组织（NA-ACCORD） 自2006年以来，代表leDEA倡议的第1区域。23个单中心和多中心临床和 NA-ACCORD的经典流行病学HIV队列包括 美国和加拿大。100多个网站提供了从19万多名艾滋病毒感染者那里收集的数据 （威尔斯亲王医院）。我们建立了强大的协作基础设施， 和专业知识的多学科小组的研究人员，跨越基础科学，临床 研究、流行病学、数据信息学和生物统计学。我们在以下方面的工作效率很高： 解决我们以前的目标和当代护理和公共卫生相关的关键问题 成人PWH我们的优势与美国卫生和公众服务部的目标特别相关。 流行病倡议，独特地提供了广泛的地理和人口范围， 建立科学平台，样本量大，广泛纵向随访> 130万 人-年，和临床数据的深度，以告知EHE的目标， 在传播停止后继续携带艾滋病毒存活。随着COVID-19的爆发， 关于COVID-19对艾滋病毒结果和艾滋病毒趋势的影响的问题 指标，以及威尔斯亲王医院的COVID-19长期结果，可以在 不-阿科德。在此背景下，我们提出了下一次融资的三个广泛目标 周期：目标1：描述艾滋病毒治疗的纵向过程、进展和结果， 北美在设置EHE倡议，这将增加数量和异质性 艾滋病毒治疗和艾滋病毒感染者的长期挑战继续， 进化目的2：评估和描述北美艾滋病毒感染的临床过程， 重点关注主要的非艾滋病合并症和合并感染、多发病和合并症， 自由预期寿命目标3：扩大和扩展我们最先进的流行病学，生物统计学， 和数据科学方法论。NA-ACCORD是一个世界级的合作项目， 已建立的艾滋病毒队列能够：a）深入了解 当对EHE做出特别努力时，艾滋病毒的过程; B）与其他人合作 艾滋病毒/艾滋病信息交换区域，为今后艾滋病毒在低收入和中等收入区域的流行提供信息;以及c） 了解艾滋病毒治疗的差异，结果和预后因素，将告知未来 全球艾滋病研究和护理。

The North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) has represented Region 1 of the leDEA initiative since 2006. The 23 single and multi-site clinical and classical epidemiologic HIV cohorts of the NA-ACCORD encompass most HIV cohorts within the US and Canada. Over 100 sites contribute data collected from over 190,000 people with HIV (PWH). We have established a strong collaborative infrastructure that capitalizes on the talents and expertise of a multi-disciplinary group of investigators that span basic science, clinical research, epidemiology, data informatics and biostatistics. We have been highly productive in addressing our previous Aims and key questions in contemporary care and public health relevant to adult PWH. Our strengths are especially relevant to the goals of the US DHHS Ending the HIV Epidemic (EHE) initiative, uniquely providing the broad geographic and demographic scope, established scientific platform, large sample size, extensive longitudinal follow-up of >1.3 million person-years, and depth of clinical data to inform the goals of EHE with rich data on those who will continue to survive with HIV after transmission is halted. With the onset of the COVID-19 pandemic, questions regarding the impact of COVID-19 on HIV outcomes and trends in HIV indicators, as well as longer-term outcomes of COVID-19 among PWH, can be answered in the NA-ACCORD. Within this context, we present three broadly-defined aims for the next funding cycle: Aim 1: Characterize the longitudinal course of HIV treatment, progression and outcomes in North America in the setting of the EHE initiative, which will increase the number and heterogeneity of those in HIV care as HIV treatment and the long-term challenges of living with HIV continue to evolve. Aim 2: To assess and characterize the clinical course of HIV infection in North America, with a focus on major non-AIDS comorbidities and co-infections, multimorbidity and comorbidity- free life expectancy. Aim 3: To expand and extend our state-of-the art epidemiologic, biostatistical, and data science methodologic approaches. The NA-ACCORD is a world-class collaboration of established HIV cohorts well-positioned to a) provide in-depth understanding of the longitudinal course of HIV when extraordinary efforts are being made to EHE; b) collaborate with the other IeDEA regions to inform the future HIV epidemics in low- and middle-income regions; and c) understand differences in HIV treatment, outcomes and prognostic factors that will inform future research and HIV care globally.